• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4658654)   Today's Articles (5474)   Subscriber (51275)
For: Veronese ME, McLean S. Debrisoquine oxidation polymorphism in a Tasmanian population. Eur J Clin Pharmacol 1991;40:529-32. [PMID: 1884730 DOI: 10.1007/bf00315235] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Number Cited by Other Article(s)
1
Jann MW, Grimsley SR. Pharmacogenetics of Agents Acting on the Central Nervous System. J Pharm Pract 2016. [DOI: 10.1177/089719009300600103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
2
Li AP. Biomarkers and human hepatocytes. Biomark Med 2014;8:173-83. [DOI: 10.2217/bmm.13.155] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]  Open
3
Smith GF. Designing drugs to avoid toxicity. PROGRESS IN MEDICINAL CHEMISTRY 2011;50:1-47. [PMID: 21315927 DOI: 10.1016/b978-0-12-381290-2.00001-x] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
4
Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2008;34:243-56. [PMID: 15204697 DOI: 10.1080/00498250310001657568] [Citation(s) in RCA: 132] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
5
Skeith KJ, Hussain MS, Coutts RT, Ramos-Remus C, Avina-Zubieta JA, Russell AS. Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. Clin Rheumatol 1997;16:291-5. [PMID: 9184268 DOI: 10.1007/bf02238966] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
6
Spina E, Campo GM, Avenoso A, Caputi AP, Zuccaro P, Pacifici R, Gatti G, Strada G, Bartoli A, Perucca E. CYP2D6-related oxidation polymorphism in Italy. Pharmacol Res 1994;29:281-9. [PMID: 8058599 DOI: 10.1016/1043-6618(94)80051-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
7
Jann MW, Lam YF. Future Directions for Pharmacogenetics. J Pharm Pract 1993. [DOI: 10.1177/089719009300600105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
8
Veronese ME, McLean S. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype. Eur J Clin Pharmacol 1991;40:547-52. [PMID: 1884734 DOI: 10.1007/bf00279967] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA